The firm is seeking approval of myChoice HRD as a test that can identify ovarian, fallopian, or peritoneal cancer patients deficient in homologous recombination DNA repair.
The project dovetails with a separate effort to sequence the whole exomes of the samples, the first 50,000 of which became available to researchers this month.
This week's news includes Illumina, Becton Dickinson, PerkinElmer, iGene Laboratory, Novacyt, Twist Bioscience, Lustgarten Foundation, and GlaxoSmithKline.
With a $300 million investment in 23andMe, GSK pivots toward personalized medicine again, while the consumer genomics firm hitches its drug development ambitions to GSK.
Pharmaceutical company GlaxoSmithKline and direct-to-consumer genetic testing company 23andMe have formed a drug discovery collaboration deal.
The companies will initially contribute equally to funding the collaboration and will share in future proceeds from drugs developed within the partnership.
The deal follows the release of a report that, among other things, urged support for genomics and other life sciences in the UK.
The alliance's first aim is the identification, development, and validation of biomarkers of cancer and treatment response.
The firms will have exclusive access for a limited time to the data from the first 50,000 individuals with samples in the biobank to be sequenced.
The study seeks to identify biomarkers that can help personalize treatment for patients by identifying signs of rapid decline in kidney function.
A Harvard University professor has been charged with making false claims regarding funds he received from China, the New York Times reports.
Discover magazine reports that animal dissections might dissuade students from science careers, but that a firm has developed synthetic frogs for dissections.
Nature News reports that a US panel is reviewing current guidelines for federally funded gain-of-function viral research.
In PNAS this week: de novo mutation patterns among the Amish, an alternative RNA-seq method, and more.